I-Corps: Technology for processing lipoaspirate for plastic surgery and regenerative medicine

该I-Corps项目更广泛的影响/商业潜力是开发一种用于处理吸脂脂肪的医疗器械，作为体内成人干细胞的来源，用于护理点美容和再生医学应用。 脂肪移植是整形外科医生进行的最常见和最通用的外科手术之一。 所提出的设备针对再生医学各个方面的即时治疗，其中需要自体干细胞（在同一个人体内衍生和使用）。 所提出的设备可以在大约15分钟内处理大量和少量的脂肪，而不使用有害的化学物质。此外，它是一个封闭的系统，旨在提供可重复的处理，以产生最高质量的脂肪用于移植和治疗应用，同时减少手术室时间和对特殊设备或技术人员的需求，使外科医生能够专注于患者而不是脂肪处理。 它可用于治疗骨关节炎和糖尿病足溃疡等严重血管疾病和难以获得护理的截肢候选人的应用。I-Corps项目是基于开发一种医疗设备来处理和部署脂肪组织和干细胞用于治疗应用。 为该平台开发的核心技术包括一个制备装置，它动态清洗脂肪组织以去除肿胀液，血液和其他水性废物;乳化和微粉化装置，它产生剪切力将脂肪组织分解成更小的单位;和过滤装置，它去除大的脂肪碎片并最大限度地提高细胞回收率。 目标是将所有三个组件联合收割机组合成一次性钉仓，该钉仓将与可重复使用的平台集成，以创建一种工具，减少手术室或临床环境中所需的手术时间和人力，同时提高外科医生和患者的可靠性和临床结局。 初步研究表明，所提出的平台产生的干细胞治疗剂具有与目前使用的标准相当的活力和细胞计数。 此外，数据显示，该设备还丰富了组织恢复的关键干细胞群体，其水平是市场上其他设备的3至4倍。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of a medical device for the processing of liposuction fat as a source of adult stem cells in the body for point-of-care aesthetic and regenerative medicine applications. Fat grafting is one of the most common and versatile surgical procedures performed by plastic and reconstructive surgeons. The proposed device targets point-of-care therapeutics in all aspects of regenerative medicine where autologous stem cells (derived and used within the same person) are required. The proposed device may enable the processing of large and small volumes of fat without the use of harmful chemicals in about 15 minutes. In addition, it is a closed system that is designed to provide reproducible processing to yield the highest quality fat for grafting and therapeutic applications, while reducing operating room time and the need for special equipment or technicians, allowing the surgeon to focus on the patient rather than fat processing. It may be used in applications such as the treatment of osteoarthritis, and diabetic foot ulcers in amputation candidates with severe vascular disease and poor access to care.This I-Corps project is based on the development of a medical device to process and deploy adipose tissue and stem cells for therapeutic applications. The core technologies developed for this platform include a preparation device, which dynamically washes fat tissue to remove tumescent fluid, blood, and other aqueous waste; an emulsification and micronization device, which generates shear forces to break down fat tissue into smaller units; and a filtration device, which removes large adipose fragments and maximizes cell recovery. The goal is to combine all three components into a single-use disposable cartridge that will integrate with a reusable platform to create a tool that decreases procedure time and manpower required in the operating room or clinical setting while improving reliability and clinical outcomes for the surgeon and the patient. Preliminary research has shown that the proposed platform generates a stem cell therapeutic with comparable viability and cell counts to the standards currently used. In addition, data show that the device also enriches stem cell populations critical to tissue recovery at 3 and 4 times the levels of other devices on the market.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.